Clinical Trial Detail

NCT ID NCT01822496
Title Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Carboplatin + Cisplatin + Erlotinib + Etoposide + Paclitaxel

Age Groups: adult

No variant requirements are available.